Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Hollandia
9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Amersfoort, Dordrecht, Leiden
- Életkor
- 18 év and over
- People
- 1046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Utrecht
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 2. fázisNot yet taking people in HollandiaHOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
- Where
- Almere, Arnhem, Delft, Deventer, Dordrecht, Emmen, Groningen, Hoofddorp, Leeuwarden, Nieuwegein, Rotterdam, 'S-Hertogenbosch, Uden, Zwolle
- Életkor
- 65 év and over
- People
- 276 worldwide
- Run by
- Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2025-524230-25-00 · EU 2025-524230-25-00 - 3. fázisTaking peoplePrevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
- Where
- Almelo, Amstelveen, Apeldoorn, Arnhem, Breda, Delft, Dordrecht, Eindhoven, Geleen, Goes, Groningen, Harderwijk, Hilversum, Hoofddorp, Nieuwegein, Nijmegen, Rotterdam, Schiedam, 's-Gravenhage, 's-Hertogenbosch, Sneek, Utrecht, Venlo, Zwolle
- Életkor
- 18 év and over
- People
- 324
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06220032 · EU 2023-505377-32-00 - No phaseTaking peopleThe TASTY-steering Study
- Where
- Amsterdam, Arnhem, Dirksland, Ede, Groningen, Nijmegen, Rotterdam, Scheemda, Veldhoven, Zwolle
- Életkor
- 18 év to 70 év
- People
- 201
- Run by
- University Medical Center Groningen
See details and how to joinNCT07258563 - 1. fázisTaking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Groningen, Nijmegen, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00 - 2. fázisTaking peopleEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Where
- Amsterdam, Groningen, Leiden, Rotterdam
- Életkor
- 18 év to 70 év
- People
- 213 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00 - 1. fázisTaking peopleTakeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma
- Where
- Groningen
- Életkor
- 18 év and over
- People
- 20
- Run by
- Universitair Medisch Centrum Groningen
See details and how to join2024-511151-18-01 · EU 2024-511151-18-01 - 1/2. fázisTaking peoplePhase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
- Where
- Amsterdam, Groningen, Maastricht, Nieuwegein, Nijmegen, Rotterdam, 's-Gravenhage, Utrecht, Zwolle
- Életkor
- 18 év to 64 év
- People
- 37 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT03356054 · EU 2023-510556-22-00